Teprotumumab N01 compared with methylprednisolone for active thyroid eye disease
Compares teprotumumab N01 with methylprednisolone in adults with active thyroid eye disease.
Key facts
- Who runs it
- Innovent Biologics (Suzhou) Co. Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 92 people, planned
- Started
- 30 Jul 2026
- Expected to end
- 30 Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Teprotumumab N01
- Methylprednisolone
- Record updated
- 13 August 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- Written informed consent
- Male or female subject between the ages of 18 and 80 years at screening
- Weight between 45 kg and 100 kg
- Moderate-to-severe active TED:; CAS ≥ 3 in the study eye at screening and baseline; Usually associated with at least two of the following: lid retraction ≥ 2 mm, moderate or severe soft tissue involvement, exophthalmos ≥ 3 mm above normal, and/or inconstant or constant diplopia; ≤ 12 months since the onset of active TED symptoms according to subjects' chief complaint or medical record at screening
- Exophthalmos ≥ 16 mm in the study eye at baseline
- Infertile female participants or fertile female participants with negative blood pregnancy test results during the screening period and agree to take contraceptive measures from screening to 120 days after the last dose; male participants should agree to use contraceptive measures from screening to 120 days after the last dose
Who cannot take part
- Participants previously diagnosed with dysthyroid optic neuropathy (DON), or with DON as determined by the investigator at screening
- Scheduled orbital radiotherapy at any time before baseline or during the study, or surgical treatment for TED, including orbital decompression, strabismus surgery, and eyelid surgery
- Oral or intravenous glucocorticoids within 30 days prior to screening
- Peribulbar/periorbital injection of glucocorticoids within 90 days prior to screening
- Oral or intravenous administration of any other non-steroidal immunosuppressants within 90 days prior to screening
- Use of glucocorticoid eye drops/ointments or use of non-steroidal immunosuppressant eye drops within 30 days prior to screening
- Received TEPEZZA or Teprotumumab N01 Injection at any time before screening
- Received CD20 antibody or interleukin-6 receptor (IL-6R) antibody at any time before screening
- Have received any other TED therapeutic drugs under development (including but not limited to biologics targeting IGF-1R, FcRn, and TSHR) at any time before screening
- Use of any other monoclonal antibody within 90 days prior to screening
- History of tinnitus or other hearing impairment in either ear during the screening period; or abnormal pure tone audiometry results (defined as an average bone conduction hearing threshold of ≥ 25 dB at 0.5, 1, 2, and 4 kHz, or a bone conduction hearing threshold of ≥ 40 dB at any frequency)
- Participants with poorly controlled thyroid function, defined as free triiodothyronine (FT3) or free thyroxine (FT4) deviating from the normal reference range of the local laboratory by more than 50% at screening
- Any other pre-existing disease, metabolic disorder, or physical examination or clinical laboratory abnormality that leads to a reasonable suspicion of a disease or condition that contraindicates the use of the investigational drug, affects the interpretation of study results, or places the participant at high risk of treatment complications
- Poorly controlled diabetes mellitus (defined as glycosylated hemoglobin ≥ 8.0% at screening)
- Participants to be excluded (Participants meeting any of the following criteria will be regarded as ineligible):
- The CAS of the study eye at baseline is reduced by ≥ 2 points compared with that at screening, or the proptosis of the study eye at baseline is reduced by ≥ 2 mm compared with that at screening
- Patients with corneal ulcers that are not relieved after treatment at the investigator's discretion
- Cumulative dose of glucocorticoids used to treat TED ≥ 1 g methylprednisolone equivalents at any time before baseline
- Female participants in pregnancy or lactation
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a multicenter, randomized, open-label, active-controlled Phase IV clinical trial in participants with active thyroid eye disease (TED). Approximately 92 eligible participants will be randomized to the teprotumumab N01 group and the intravenous glucocorticoid (IVGC) group in a 1:1 ratio on Day 1. The randomization stratification factor is diplopia at baseline (Gorman diplopia score ≥1 vs. Gorman diplopia score = 0).
The 2 groups in the trial
- Intravenous glucocorticoid (IVGC) groupExisting treatment, for comparison
Treatment: Methylprednisolone
- Teprotumumab N01 groupTreatment being tested
Treatment: Teprotumumab N01
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Randomized, Open-Label, Active-Controlled Phase IV Clinical Study to Evaluate the Efficacy and Safety of Teprotumumab N01 in the Treatment of Active Thyroid Eye Disease
- Plain-language title
- Teprotumumab N01 compared with methylprednisolone for active thyroid eye diseaseGenerated from the registry record. The registry title is the official one.
- Fit questions
- Built from NCT07265258, who can take part
- Record updated
- 13 August 2026